BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Gaba RC. Chemoembolization Practice Patterns and Technical Methods Among Interventional Radiologists: Results of an Online Survey. American Journal of Roentgenology 2012;198:692-9. [DOI: 10.2214/ajr.11.7066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
2 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
3 Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers. Radiology 2015;275:438-47. [PMID: 25531387 DOI: 10.1148/radiol.14141180] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
4 Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, Salem R, Lewandowski RJ. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2012;35:1094-1101. [PMID: 22069121 DOI: 10.1007/s00270-011-0292-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
5 Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268:431-439. [PMID: 23616632 DOI: 10.1148/radiol.13121637] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
6 Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer. 2013;49:826-834. [PMID: 22995582 DOI: 10.1016/j.ejca.2012.08.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
7 Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S, Ingrand P, Tasu JP. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26:1640-1648. [PMID: 26455721 DOI: 10.1007/s00330-015-3982-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
8 Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017;23:3690-701. [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
10 Ali R, Riaz A, Gabr A, Abouchaleh N, Mora R, Al Asadi A, Caicedo JC, Abecassis M, Katariya N, Maddur H, Kulik L, Lewandowski RJ, Salem R. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging 2017;44:2195-202. [DOI: 10.1007/s00259-017-3792-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
11 Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Sci Rep 2020;10:18026. [PMID: 33093524 DOI: 10.1038/s41598-020-75120-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gaba RC, Emmadi R, Parvinian A, Casadaban LC. Correlation of Doxorubicin Delivery and Tumor Necrosis after Drug-eluting Bead Transarterial Chemoembolization of Rabbit VX2 Liver Tumors. Radiology 2016;280:752-61. [PMID: 26967144 DOI: 10.1148/radiol.2016152099] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
13 Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology. J Hepatol. 2017;67:1213-1221. [PMID: 28823713 DOI: 10.1016/j.jhep.2017.07.030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
14 Riaz A, Salem R. Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. J Vasc Interv Radiol 2019;30:1893-4. [PMID: 31757337 DOI: 10.1016/j.jvir.2019.09.003] [Reference Citation Analysis]
15 Yang K, Sung PS, You YK, Kim DG, Oh JS, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response. HPB 2019;21:1718-26. [DOI: 10.1016/j.hpb.2019.04.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria. J Vasc Interv Radiol 2013;24:316-25. [PMID: 23312990 DOI: 10.1016/j.jvir.2012.10.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
17 Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062-1069. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 140] [Cited by in F6Publishing: 126] [Article Influence: 11.7] [Reference Citation Analysis]
18 Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012;18:727-736. [PMID: 22344899 DOI: 10.1002/lt.23413] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 7.4] [Reference Citation Analysis]
19 Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P, Pandey P, Zarghampour M, Fouladi D, Liddell R, Anders RA, Kamel IR. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol. 2018;28:3032-3040. [PMID: 29383518 DOI: 10.1007/s00330-017-5198-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
20 Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clinics in Liver Disease 2017;21:231-51. [DOI: 10.1016/j.cld.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Mikhail AS, Pritchard WF, Negussie AH, Krishnasamy VP, Amchin DB, Thompson JG, Wakim PG, Woods D, Bakhutashvili I, Esparza-Trujillo JA, Karanian JW, Willis SL, Lewis AL, Levy EB, Wood BJ. Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model. Radiology 2018;289:396-404. [PMID: 30106347 DOI: 10.1148/radiol.2018172571] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
22 Lehrke HD, Heimbach JK, Wu TT, Jenkins SM, Gores GJ, Rosen CB, Mounajjed T. Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. Am J Surg Pathol. 2016;40:510-518. [PMID: 26752544 DOI: 10.1097/pas.0000000000000588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 4.2] [Reference Citation Analysis]
23 Kielar AZ, Hibbert RM, Maturen KE. Imaging after local tumor therapies: kidney and liver. Semin Roentgenol 2013;48:273-84. [PMID: 23796378 DOI: 10.1053/j.ro.2013.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 12.1] [Reference Citation Analysis]
25 Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 2014;273:746-58. [PMID: 25028783 DOI: 10.1148/radiol.14140033] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 8.5] [Reference Citation Analysis]
26 Kim JW, Seong J, Park MS, Kim KS, Park YN, Han KH, Keum KC, Lee IJ. Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery: Radiotherapy for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2016;31:1619-27. [DOI: 10.1111/jgh.13334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. Journal of Hepatology 2012;56:464-73. [DOI: 10.1016/j.jhep.2011.07.012] [Cited by in Crossref: 173] [Cited by in F6Publishing: 175] [Article Influence: 17.3] [Reference Citation Analysis]
28 Shah RP, Brown KT, Sofocleous CT. Arterially directed therapies for hepatocellular carcinoma. AJR Am J Roentgenol. 2011;197:W590-W602. [PMID: 21940531 DOI: 10.2214/ajr.11.7554] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
29 Wang D, Gaba RC, Jin B, Riaz A, Lewandowski RJ, Ryu RK, Sato KT, Ragin AB, Kulik LM, Mulcahy MF, Salem R, Larson AC, Omary RA. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011;18:828-36. [PMID: 21669349 DOI: 10.1016/j.acra.2011.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
30 Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, Bedossa P, Vilgrain V, Roncalli M, Paradis V. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int. 2015;Epub ahead of print. [PMID: 25865109 DOI: 10.1111/liv.12844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
31 Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology. 2013;58:1655-1666. [PMID: 23703789 DOI: 10.1002/hep.26487] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
32 Tohme S, Sukato D, Chen HW, Amesur N, Zajko AB, Humar A, Geller DA, Marsh JW, Tsung A. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol. 2013;24:1632-1638. [PMID: 24160821 DOI: 10.1016/j.jvir.2013.07.026] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 6.5] [Reference Citation Analysis]
33 Kim BK, Kim KA, Kim M, Park JY, Kim DY, Ahn SH, Han K, Kim SU, Park M. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. Digestive and Liver Disease 2015;47:682-8. [DOI: 10.1016/j.dld.2015.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
34 Liu L, Zhao Y, Jia J, Chen H, Bai W, Yang M, Yin Z, He C, Zhang L, Guo W, Niu J, Yuan J, Cai H, Xia J, Fan D, Han G. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. Sci Rep 2016;6:19851. [PMID: 26831408 DOI: 10.1038/srep19851] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
35 Gaba RC, Lewandowski RJ, Hickey R, Baerlocher MO, Cohen EI, Dariushnia SR, Janne d'Othée B, Padia SA, Salem R, Wang DS, Nikolic B, Brown DB; Society of Interventional Radiology Technology Assessment Committee. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol 2016;27:457-73. [PMID: 26851158 DOI: 10.1016/j.jvir.2015.12.752] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
36 Lam A, Fernando D, Sirlin CC, Nayyar M, Goodwin SC, Imagawa DK, Lall C. Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation. Clin Radiol 2017;72:994.e9-994.e16. [PMID: 28779950 DOI: 10.1016/j.crad.2017.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Degrauwe N, Hocquelet A, Digklia A, Schaefer N, Denys A, Duran R. Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. Front Pharmacol 2019;10:450. [PMID: 31143114 DOI: 10.3389/fphar.2019.00450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
38 Puza CJ, Wang Q, Kim CY. Evaluation of the Heat Sink Effect After Transarterial Embolization When Performed in Combination with Thermal Ablation of the Liver in a Rabbit Model. Cardiovasc Intervent Radiol 2018;41:1773-8. [PMID: 30039505 DOI: 10.1007/s00270-018-2034-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
39 Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82:e212-e218. [PMID: 23332890 DOI: 10.1016/j.ejrad.2012.12.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
40 Patel T, Harnois D. Assessment of response to therapy in hepatocellular carcinoma. Ann Med 2014;46:130-7. [PMID: 24716738 DOI: 10.3109/07853890.2014.891355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
41 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Moschouris H, Malagari K, Papadaki MG, Kornezos I, Gkoutzios P, Tepelenis N, Matsaidonis D. Short-term evaluation of liver tumors after transarterial chemoembolization: limitations and feasibility of contrast-enhanced ultrasonography. Abdom Imaging 2011;36:718-28. [PMID: 21253722 DOI: 10.1007/s00261-011-9690-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
43 Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol 2020;35:305-13. [PMID: 31369166 DOI: 10.1111/jgh.14816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24:509-517. [PMID: 23428355 DOI: 10.1016/j.jvir.2012.12.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
45 Ettorre GM, Levi Sandri GB, Santoro R, Lepiane P, Colasanti M, Vennarecci G. Bridging and downstaging to transplantation in hepatocellular carcinoma. Future Oncol 2014;10:61-3. [PMID: 25478770 DOI: 10.2217/fon.14.226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
46 Garin E, Pallard X, Edeline J. Does Y90 Radioembolization Prolong Overall Survival Compared With Chemoembolization in Patients With Hepatocellular Carcinoma? Gastroenterology. 2017;152:1624-1625. [PMID: 28371622 DOI: 10.1053/j.gastro.2017.01.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
48 Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE, Gaba RC. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes. American Journal of Roentgenology 2016;206:645-54. [DOI: 10.2214/ajr.15.14758] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Miller FH, Lopes Vendrami C, Gabr A, Horowitz JM, Kelahan LC, Riaz A, Salem R, Lewandowski RJ. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics 2021;41:1802-18. [PMID: 34559587 DOI: 10.1148/rg.2021210014] [Reference Citation Analysis]
50 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 108] [Article Influence: 10.3] [Reference Citation Analysis]
51 Rimola J, Davenport MS, Liu PS, Brown T, Marrero JA, Mckenna BJ, Hussain HK. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. Abdom Radiol 2019;44:549-58. [DOI: 10.1007/s00261-018-1775-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
52 Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, Ravaioli M, D'Errico-Grigioni A, Pinna AD, Bolondi L. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011;53:1580-1589. [PMID: 21351114 DOI: 10.1002/hep.24246] [Cited by in Crossref: 157] [Cited by in F6Publishing: 149] [Article Influence: 14.3] [Reference Citation Analysis]
53 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
54 Odisio BC, Galastri F, Avritscher R, Afonso BB, Segatelli V, Felga GE, Salvalaggio PR, Ensor J, Wallace MJ, Nasser F. Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization. Cardiovasc Intervent Radiol. 2014;37:1018-1026. [PMID: 24149832 DOI: 10.1007/s00270-013-0759-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
55 Shah KY, Gaba RC. Combined Transarterial Chemoembolization and Percutaneous Radiofrequency Ablation: More Promising Evidence of Effectiveness in Treating Solitary, Medium-Sized Hepatocellular Carcinoma. J Vasc Interv Radiol 2019;30:1545-8. [PMID: 31547921 DOI: 10.1016/j.jvir.2019.07.005] [Reference Citation Analysis]
56 Floridi C, Pesapane F, Angileri SA, De Palma D, Fontana F, Caspani F, Barile A, Del Sole A, Masciocchi C, Lucignani G, Carrafiello G. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-1021-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
57 Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim M. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 2014;34:305-12. [DOI: 10.1111/liv.12270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
58 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
59 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
60 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
61 Zhang W, Xu AH, Wang W, Wu YH, Sun QL, Shu C. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. BMC Cancer 2019;19:1041. [PMID: 31690274 DOI: 10.1186/s12885-019-6265-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
62 Gaba RC, Groth JV, Parvinian A, Guzman G, Casadaban LC. Gene expression in hepatocellular carcinoma: pilot study of potential transarterial chemoembolization response biomarkers. J Vasc Interv Radiol 2015;26:723-32. [PMID: 25724086 DOI: 10.1016/j.jvir.2014.12.610] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
63 Stampfl U, Bermejo JL, Sommer CM, Hoffmann K, Weiss KH, Schirmacher P, Schemmer P, Kauczor HU, Richter GM, Radeleff BA. Efficacy and nontarget effects of transarterial chemoembolization in bridging of hepatocellular carcinoma patients to liver transplantation: a histopathologic study. J Vasc Interv Radiol. 2014;25:1018-1026.e4. [PMID: 24768235 DOI: 10.1016/j.jvir.2014.03.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
64 Kim KW, Lee JM, Choi BI. Assessment of the treatment response of HCC. Abdom Imaging. 2011;36:300-314. [PMID: 21279353 DOI: 10.1007/s00261-011-9683-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
65 Park WH, Shim JH, Han SB, Won HJ, Shin YM, Kim KM, Lim YS, Lee HC. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2012;23:927-36. [PMID: 22633621 DOI: 10.1016/j.jvir.2012.04.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
66 Delaney LJ, Tantawi M, Wessner CE, Machado P, Forsberg F, Lyshchik A, O'Kane P, Liu JB, Civan J, Tan A, Anton K, Shaw CM, Eisenbrey JR. Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences. Ultrasound Med Biol 2021;47:2523-31. [PMID: 34130880 DOI: 10.1016/j.ultrasmedbio.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D, Pawlik TM, Diaz LA, Bhagat N, Eng J. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology. 2013;266:502-513. [PMID: 23192780 DOI: 10.1148/radiol.12120495] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
68 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 10.6] [Reference Citation Analysis]